Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (191-200 of 383) with videos related to

Pageof 39
Sort By:
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
Nature Communications|March 23, 2018
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemiaJason X Cheng, Li Chen, Yuan Li, et al.
Investigational New Drugs|December 9, 2014
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasiaOlatoyosi Odenike, Anna Halpern, Lucy A Godley, et al.
Seminars in Oncology|March 23, 2011
An integrated genomic approach to the assessment and treatment of acute myeloid leukemiaLucy A Godley, John Cunningham, M Eileen Dolan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopeniaHagop Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag, Stephen L George, Edward J Lee, et al.
Leukemia & Lymphoma|June 12, 2010
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplantLucy A Godley, Uchenna O Njiaju, Margaret Green, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older AdultsStephanie B Tsai, Joanna Rhodes, Hongtao Liu, et al.
Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.
Pageof 39

Showing results (191-200 of 383) with videos related to

Sort By:
Pageof 39
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
Nature Communications|March 23, 2018
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemiaJason X Cheng, Li Chen, Yuan Li, et al.
Investigational New Drugs|December 9, 2014
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasiaOlatoyosi Odenike, Anna Halpern, Lucy A Godley, et al.
Seminars in Oncology|March 23, 2011
An integrated genomic approach to the assessment and treatment of acute myeloid leukemiaLucy A Godley, John Cunningham, M Eileen Dolan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopeniaHagop Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag, Stephen L George, Edward J Lee, et al.
Leukemia & Lymphoma|June 12, 2010
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplantLucy A Godley, Uchenna O Njiaju, Margaret Green, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 31, 2017
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older AdultsStephanie B Tsai, Joanna Rhodes, Hongtao Liu, et al.
Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.
Pageof 39